West Pharmaceutical Services Gains Spotlight In S&P 500 Momentum
West Pharmaceutical Services (WST) is attracting attention within the S&P 500 due to its role in healthcare packaging and injectable delivery solutions. The article highlights the increasing demand for specialized pharmaceutical delivery systems driven by pharmaceutical innovation, particularly in injectable therapies and biologic medicines. The company's focus on advanced drug manufacturing and specialized healthcare supply chain operations positions it well within the current market trends.
BD Launches Elyra Thulium Fiber Laser System for Kidney Stone Care
BD (Becton, Dickinson and Company) has launched the Elyra Thulium Fiber Laser (TFL) System, an advanced medical device designed to improve efficiency and versatility in kidney stone management and soft tissue procedures. This new system, available in two configurations, uses advanced TFL technology to streamline kidney stone treatment and boasts an intuitive user interface and rapid startup. Despite the innovation, BD's stock saw a slight dip, but the company anticipates long-term growth by strengthening its urologic stone management portfolio in a growing market.
Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Centene (CNC)
Bank of America Securities analysts have issued bullish ratings on several healthcare stocks, including Belite Bio, Inc. ADR (BLTE) and Centene (CNC). Tazeen Ahmad maintained a Buy rating on Belite Bio, Inc. ADR with a consensus price target indicating a significant upside. Kevin Fischbeck also maintained a Buy rating on Centene, and Michael Ryskin reiterated a Buy rating on West Pharmaceutical Services, highlighting potential upsides for these companies.
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Inogen (INGN) is positioned for growth due to its strong portable oxygen concentrator (POC) market prospects, expanding product portfolio, and international market momentum, despite U.S. revenue pressures. The company is increasing R&D investment and expects continued business improvements, with an attractive valuation based on its P/S ratio. Key risks include macroeconomic factors, supply chain exposure, and reliance on reimbursement for rental economics.
West Pharmaceutical restores operations after cyberattack
West Pharmaceutical Services has successfully restored its operations following a recent cyberattack. The company, based in Exton, Pa., announced the restoration on May 22, 2026. This news comes after a period of disruption caused by the cyber incident.
S&P 500 Stock Picks: Avoid eBay and West Pharma, Buy Hubbell in 2026 - News and Statistics
A report from StockStory published by IndexBox recommends avoiding eBay and West Pharmaceutical Services while buying Hubbell in May 2026. eBay is flagged due to uneven growth in active buyers, fragile sales demand, and declining EBITDA margins. West Pharmaceutical Services faces concerns over slower-than-average sales growth for healthcare companies, rising costs, and eroding returns on capital. Conversely, Hubbell is presented as a strong buy due to its solid revenue growth, accelerated earnings per share through share buybacks, and expanding free cash flow margins.
West Pharmaceutical Shares Rise After Update on Restoration of Core Enterprise Systems Following Cyberattack
West Pharmaceutical Services (WPS) shares rose after the company provided an update on the restoration of its core enterprise systems following a cyberattack. The company confirmed that key systems are operational and that its global manufacturing facilities are producing and shipping products. This progress has led to an improved outlook and positive investor reaction.
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day
Shares of West Pharmaceutical Services Inc. (WST) rose 3.48% on Thursday, closing at $316.13, outperforming the broader market. The S&P 500 Index and the Dow Jones Industrial Average also saw gains, rising 0.17% and 0.55% respectively. This marks the second consecutive day of gains for West Pharmaceutical Services Inc. stock.
Q1 Earnings Recap: West Pharmaceutical Services (NYSE:WST) Tops Drug Development Inputs & Services Stocks
West Pharmaceutical Services (NYSE:WST) led the drug development inputs & services industry in Q1, reporting strong revenues of $844.9 million, up 21% year-on-year, and exceeding analyst expectations. The company attributed its success to continued market demand and increased production, particularly in Europe, and subsequently raised its full-year 2026 guidance. While the broader drug development inputs & services sector saw a collective decline in share prices despite revenues beating estimates, West Pharmaceutical Services and Fortrea (NASDAQ:FTRE) showed significant stock increases post-earnings, with Azenta (NASDAQ:AZTA) and Charles River Laboratories (NYSE:CRL) facing declines.
Robotic surgery gets telepresence, force-sensing tools in Intuitive upgrade
Intuitive (Nasdaq: ISRG) announced significant innovations for its da Vinci 5 robotic surgical system, including enhanced telepresence capabilities, expanded uses for Force Feedback instruments, and improved product reliability and security. These updates aim to advance patient care, optimize surgeon experience, and reduce costs, with features like a full-OR telepresence camera, mobile console login, new training modules, and an anticipated increase in instrument uses by 2027. The company also highlighted strong da Vinci 5 adoption, with over 1,400 systems installed globally and 380,000 procedures performed, along with a guaranteed 98% uptime exceeding 99% actual performance.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
West Pharmaceutical Services (WST) is a strong buy due to robust demand for its High-Value Product (HVP) components, expanding GLP-1 drug programs, and Annex 1 regulatory conversions. Despite concerns about tariff impacts and destocking, the company shows significant operational improvements and margin expansion. Its strong market position and positive earnings estimates make it an attractive investment, although the SmartDose divestiture presents a short-term revenue headwind.
West Pharmaceutical Services returns to full operations following cybersecurity attack
West Pharmaceutical Services announced that it has fully restored operations across all its sites after experiencing a cybersecurity attack earlier this month. The company believes the incident will not materially impact its 2026 financial outlook, despite data theft and system lockouts. While investigation continues, no further unauthorized access has been detected, and analysts remain encouraged by the company's quick recovery.
Q1 Earnings Recap: West Pharmaceutical Services (NYSE:WST) Tops Drug Development Inputs & Services Stocks
West Pharmaceutical Services (NYSE:WST) reported a strong Q1, significantly exceeding revenue and adjusted EPS expectations with 21% year-on-year revenue growth. The company raised its full-year 2026 guidance, driven by robust demand for its High Value Products Components business. Fortrea (NASDAQ:FTRE) also had a strong quarter, beating EPS and revenue estimates, while Azenta (NASDAQ:AZTA) delivered the weakest performance against analyst estimates, with revenues falling short of expectations.
Cyber incident update: West Pharmaceutical (NYSE: WST) restores operations
West Pharmaceutical Services (NYSE: WST) has filed an amended report detailing the recovery from a material cybersecurity attack. The company reported that core enterprise systems are restored and global operations, including manufacturing, receiving, and shipping, are fully functional. West Pharmaceutical believes the incident will not materially impact its 2026 second-quarter and full-year financial guidance.
West Pharma says fully operational after cyberattack, sees no hit to 2026 forecast
West Pharmaceutical Services has announced that it has fully restored operations after a cybersecurity attack earlier this month. The company does not anticipate any material impact on its 2026 financial outlook and continues its investigation, having found no further unauthorized access. Analysts are encouraged by the company's quick return to normal operations and ability to offset disruptions.
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
Pacific Biosciences (PACB) has partnered with Blank Bio, an AI research company, to advance RNA foundation models for precision oncology, including a $7.2 million seed investment. Blank Bio will utilize PacBio’s HiFi long-read sequencing technology to generate RNA sequencing data from tumor samples, with the goal of improving biomarker discovery, diagnostics, and clinical trial design. This collaboration aims to strengthen PacBio's position in the oncology market and expand the application of its technology in AI-driven precision medicine.
Cyberattack Fallout Sends West Pharmaceutical Stock Sliding
West Pharmaceutical Services (WST) stock is experiencing volatility and sliding due to the fallout from a major ransomware attack disclosed in May 2026. This cyberattack led to data theft and the encryption of key IT systems, causing investors to be wary about the recovery timeline and financial impact. The stock's decline is driven by company-specific concerns regarding operational stability and potential reputational damage, rather than broader market trends.
DXCM to Launch Dexcom Flex CGM System for Type 2 Diabetes in Germany
DexCom (DXCM) is set to launch its new Dexcom Flex continuous glucose monitoring (CGM) system in Germany, targeting adults with Type 2 diabetes who are not on intensive insulin therapy. This move aims to broaden access to CGM technology, aligning with the company's strategy to enhance personalized care for a wider patient population. The launch is expected to strengthen DexCom's market position, support long-term revenue growth, and capitalize on the expanding diabetes technology market.
West Declares Quarterly Dividend
West Pharmaceutical Services Inc. (WST) has declared a quarterly dividend. The announcement was made via a press release and was quickly disseminated to Quantisnow Plus members. Quantisnow, a platform for retail investors, highlights this and other market intelligence such as SEC filings and insider trades.
Does West Pharmaceutical (WST) Post-Cyberattack Rebound Quietly Reshape Its Higher-Margin Growth Story?
West Pharmaceutical Services (WST) recently experienced a cyberattack but has successfully restored its global operations, including its largest plant in Germany. This rapid recovery reinforces the company's operational resilience and its crucial role in the injectable drug packaging supply chain. While the cyber incident highlighted a key risk, it has not significantly altered the company's long-term growth narrative focused on higher-margin components and projected revenue of $3.8 billion by 2029.
Does West Pharmaceutical (WST) Post-Cyberattack Rebound Quietly Reshape Its Higher-Margin Growth Story?
West Pharmaceutical Services (WST) has rapidly recovered from a May 2026 cyberattack, restoring full operations at key facilities, including its largest plant in Germany. This operational resilience reinforces its investment narrative of higher-margin growth in injectable drug packaging, despite cyber risks and shareholder dissent on an independent board chair. The company's future projections include $3.8 billion revenue and $751.8 million earnings by 2029, suggesting a potential 15% upside to its current price according to Simply Wall St's fair value estimate.
NTRA's Signatera CDx Wins FDA Nod in Muscle-Invasive Bladder Cancer
Natera, Inc. (NTRA) announced that its Signatera CDx received FDA approval as a companion diagnostic for adjuvant atezolizumab immunotherapy in patients with muscle-invasive bladder cancer (MIBC). This marks the first companion diagnostic approval in blood-based minimal residual disease (MRD) testing and is expected to significantly advance personalized oncology care. The approval is supported by positive findings from the Phase III IMvigor011 trial, which demonstrated improved outcomes for MRD-positive patients and the potential for personalized treatment decisions for MRD-negative patients.
18th May – Threat Intelligence Report
This threat intelligence report for May 18, 2026, details recent cyber incidents including breaches at Vodafone, THORChain, West Pharmaceutical Services, and Foxconn. It also covers AI-related threats such as vulnerabilities in an AI agent platform, an AI-assisted macOS kernel exploit, and the abuse of AI website generators for phishing. The report additionally highlights critical vulnerabilities and patches for Windows zero-days, NGINX, Cisco, and Apple products, alongside recent threat intelligence reports from Check Point Research regarding ransomware trends and cyber activity surges.
Zacks Research Analysts Raise Earnings Estimates for WST
Zacks Research analysts have increased their Q2 2026 EPS estimates for West Pharmaceutical Services (NYSE:WST) from $1.98 to $2.06 and maintained a "Strong-Buy" rating. The firm also raised longer-term earnings forecasts through FY2028. This update follows West Pharmaceutical Services' recent earnings beat, reporting $2.13 EPS and $844.9 million in revenue, exceeding analyst expectations.
Is It Too Late To Consider West Pharmaceutical Services (WST) After Recent $1b Buyback Plan?
West Pharmaceutical Services (WST) is currently trading at US$302.89 per share. A Discounted Cash Flow (DCF) analysis suggests the stock might be overvalued by 45.6% with an estimated intrinsic value of $207.98. Its P/E ratio of 39.43x is also above both the industry average and its proprietary Fair Ratio, indicating it is priced at a premium.
Is It Too Late To Consider West Pharmaceutical Services (WST) After Recent $1b Buyback Plan?
This article analyzes West Pharmaceutical Services (WST) post a $1 billion buyback plan, evaluating its current valuation. Using a Discounted Cash Flow (DCF) model and Price-to-Earnings (P/E) ratio, the analysis suggests the stock is overvalued by 45.6% and trades at a premium compared to industry peers. The article encourages investors to use "Narratives" for personalized valuation based on their own forecasts.
West Pharmaceutical Cyberattack Tests Operational Resilience And Investor Risk Assumptions
West Pharmaceutical Services (NYSE:WST) experienced a significant cyberattack involving data exfiltration and system encryption, leading to a temporary halt in global operations as the company works on containment and restoration. This incident raises questions about prolonged operational disruption, potential financial impacts, and data privacy implications for investors, especially given the company's strong recent stock performance. The situation highlights the growing importance of cybersecurity in operational resilience, regulatory exposure, and governance for companies deeply integrated into global supply chains.
West Pharmaceutical Cyberattack Tests Operational Resilience And Investor Risk Assumptions
West Pharmaceutical Services (NYSE:WST) experienced a material cybersecurity incident involving data exfiltration and system encryption, leading to a temporary suspension of global operations. This event prompts investors to consider not just temporary downtime, but also potential regulatory scrutiny, data privacy obligations, and legal claims, challenging the company's operational resilience narrative. The article advises focusing on the speed of operational restoration, disclosures about accessed data, and the cost of remediation to assess the long-term impact on WST's stock.
West Pharmaceutical Services Inc recently announced that the company has continued to make significant progress in restoring operations after responding to a global cyberattack incident.
West Pharmaceutical Services Inc. has announced significant progress in restoring operations after a global cyberattack. The company's systems and services are steadily returning to normal as they gradually restart global operations in a safe and controlled manner. West Pharmaceutical Services is committed to minimizing client impact, ensuring supply chain integrity, and strengthening its cybersecurity defenses.
Here's Why You Should Add Pediatrix Medical to Your Portfolio Now
Pediatrix Medical (MD) is positioned for growth due to strong cash collections, a favorable payer mix, higher patient acuity in neonatology, and strategic acquisitions. The company's shares have risen 9.7% year-to-date, contrasting with an industry decline. Despite its potential
West Pharmaceutical Services Inc announced that its High Value Product (HVP) sites, standard packaging sites, and HVP delivery device sites have now fully resumed shipping and receiving operations.
West Pharmaceutical Services Inc. has announced that its High Value Product (HVP) sites, standard packaging sites, and HVP delivery device sites have fully resumed shipping and receiving operations. All relevant facilities are now operating normally and are capable of handling customer orders for receipt and delivery. This ensures the company's ability to process and fulfill product orders without interruption.
West Pharma drops after cyber attack
West Pharmaceutical Services (WPS) shares dropped significantly after the company disclosed a cyber attack that disrupted its global operations. The attack led to a shutdown of their systems to contain the threat, impacting manufacturing and distribution. West Pharma is working to restore its systems and has engaged cybersecurity experts.
[Form 4] WEST PHARMACEUTICAL SERVICES INC Insider Trading Activity
Shane Alden Campbell, Senior Vice President of West Pharmaceutical Services, reported routine equity compensation activity involving the exercise of restricted stock units (RSUs) and related tax-withholding dispositions. On May 12, 2026, he converted 473.593 and 295.995 RSUs into common shares, while 134.927 and 84.329 shares were disposed of to cover tax liabilities. These transactions are compensation-related and do not represent open-market buying or selling.
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Revvity, Inc. (RVTY) announced that its subsidiary, Immunodiagnostic Systems (IDS), received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This new assay, alongside existing FDA-cleared tests for free testosterone and sex hormone-binding globulin, creates a comprehensive automated testosterone testing solution on a single platform, enhancing diagnostic capabilities for androgen-related conditions in both men and women. Despite a recent dip in share price, this expansion is expected to strengthen Revvity's position in the growing endocrine diagnostics market, which is projected to reach $15.69 billion by 2026.
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay
Revvity, Inc. (RVTY) announced that its subsidiary, Immunodiagnostic Systems (IDS), received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This approval expands Revvity's endocrine diagnostics portfolio, offering a comprehensive automated testosterone testing solution alongside existing assays for free testosterone and SHBG. The company expects the clearance to strengthen its market position, especially given the anticipated growth in the endocrine testing market.
West Pharmaceutical starts restoring operations after ransomware attack
West Pharmaceutical, a major maker of drug-delivery devices, has begun restoring operations after a ransomware attack that resulted in data theft and encryption. The company discovered unusual activity on May 4, hired forensic experts, and notified law enforcement, with Palo Alto Networks Unit 42 handling the incident response. While manufacturing, shipping, and receiving are restarting in some locations, the full financial impact of the attack, which temporarily disrupted global business operations, is still being assessed.
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HealthEquity (HQY) stock is recommended for holding, primarily due to its strong fourth-quarter fiscal 2026 performance, growth in Health Savings Accounts (HSAs), and advancements in AI and digital innovation driving efficiency. The company demonstrated robust account growth and significant improvements in gross and operating margins. However, potential data security threats remain a key concern for the company.
Ransomware attacks on West Pharmaceutical and Foxconn highlight growing cyber risks to manufacturing sector
Recent ransomware attacks on West Pharmaceutical Services and Foxconn underscore the escalating cyber threats faced by the manufacturing sector, impacting operations and supply chains globally. West Pharmaceutical experienced significant disruption due to data exfiltration and system encryption, while Foxconn confirmed a cyberattack involving 8TB of stolen data, including sensitive customer project documentation. These incidents highlight the critical need for robust cybersecurity measures, data inventory management, and resilience planning in industrial and supply chain environments.
Analysts Have Conflicting Sentiments on These Healthcare Companies: West Pharmaceutical Services (WST), CalciMedica (CALC) and Tyra Bioscience (TYRA)
This article summarizes analyst ratings for three healthcare companies: West Pharmaceutical Services (WST), CalciMedica (CALC), and Tyra Bioscience (TYRA). Analysts provided a Moderate Buy rating for WST with an 11.9% upside, a Moderate Buy rating for CALC with a significant projected price target, and a Strong Buy rating for TYRA with a 46.3% upside from current levels. The article highlights individual analyst performances and their respective price targets.
West Pharmaceutical says hackers stole data, encrypted systems
West Pharmaceutical Services has disclosed a cyberattack that led to data exfiltration and system encryption. The company detected the intrusion on May 4th and has since been working to restore its systems and investigate the scope of the breach. While core operations are partially restored, the full financial impact is still being assessed.
West Pharmaceutical Services hit by ransomware attack | brief | SC Media
West Pharmaceutical Services is recovering from a ransomware attack that impacted its global operations starting May 4. The company proactively shut down affected systems and engaged Unit 42 for incident response. Attackers reportedly exfiltrated data before deploying ransomware, and the investigation into the extent of data compromise and potential financial impact is ongoing.
West Pharmaceutical Services Hit by Disruptive Ransomware Attack
West Pharmaceutical Services, a global manufacturer of pharmaceutical packaging and delivery systems, experienced a disruptive ransomware attack on May 4, 2026, leading to a global shutdown of affected infrastructure. The company filed an 8-K with the SEC, indicating data exfiltration occurred before ransomware deployment and that measures were taken to mitigate data dissemination. While core systems are being restored, the incident highlights supply chain vulnerabilities in the pharmaceutical sector and the need for robust incident response plans that address data exfiltration alongside operational recovery.
West Pharmaceutical Services Inc. stock underperforms Wednesday when compared to competitors
West Pharmaceutical Services Inc. (WST) stock dropped 3.10% on Wednesday, closing at $302.40. This underperformance occurred on a mixed trading day, with the S&P 500 Index rising 0.58% and the Dow Jones Industrial Average falling 0.14%. This marks the third consecutive day of losses for West Pharmaceutical Services Inc. shares.
NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised
NeuroPace (NPCE) reported a narrower-than-expected adjusted loss per share and better-than-expected revenues in the first quarter of 2026, primarily driven by strong RNS System sales. The company raised its full-year 2026 revenue guidance to $99 million-$101 million and anticipates an improved adjusted EBITDA loss. NeuroPace also highlighted advancements in its AI-driven ECoG Assistant platform and multimodal foundational AI model, aiming to enhance epilepsy care.
BofA Securities Maintains West Pharmaceutical Services(WST.US) With Buy Rating
BofA Securities has reiterated its Buy rating for West Pharmaceutical Services (WST.US). This indicates a continued positive outlook from the financial institution regarding the company's stock.
West Pharmaceutical warns of ransomware attack impacting business operations
West Pharmaceutical, a major pharmaceutical company, has reported a ransomware attack that occurred on May 4, stealing data and encrypting systems. The incident temporarily disrupted global business operations, including shipping, receiving, and manufacturing, though core systems are being restored. The company is investigating the extent of data theft and financial impact with assistance from Palo Alto Networks’ Unit 42.
West Pharmaceutical Services Inc. stock underperforms Tuesday when compared to competitors
West Pharmaceutical Services Inc. (WST) stock fell by 3.17% on Tuesday, closing at $312.07. This performance lagged behind the broader market, as the Dow Jones Industrial Average saw a slight increase, while the S&P 500 Index experienced a minor decline. This marks the second consecutive day of losses for the company's stock.
West Pharma drops after cyber attack (WST:NYSE)
Shares of West Pharmaceutical Services (WST) fell for the second consecutive day after the company reported that a recent cybersecurity incident has affected its global business operations. The Pennsylvania-based life sciences company disclosed the impact in a regulatory filing on Monday.
West Pharma (WST) Faces Cybersecurity Attack, Stock Drops 3.6%
West Pharmaceutical Services (WST) experienced a 3.6% stock price decline after reporting a cybersecurity breach on May 4, 2026, where unauthorized parties accessed and encrypted data. Despite the setback, GuruFocus identifies WST as 13.2% undervalued with a strong GF Score of 96/100, suggesting potential for investors. The company is actively recovering from the incident, with core systems back online for some operations, but the full financial impact is still being assessed.
GE HealthCare Expands SIGNA MR Portfolio With AI-Powered Tools
GE HealthCare (GEHC) has unveiled significant advancements in its SIGNA MR portfolio, incorporating AI-powered tools to enhance research discovery and clinical impact. These innovations, set to be showcased at the ISMRM 2026 Annual Meeting, include Sonic DL for improved imaging, the SIGNA One AI-powered workflow ecosystem, and helium-efficient MRI systems like SIGNA Sprint with Freelium. Despite a recent drop in stock price, these technological enhancements are expected to strengthen GE HealthCare's position in the growing magnetic resonance imaging market.
